Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a systematic review and network meta-analysis

[1]  May Y. Choi,et al.  Randomized controlled trials of biologic treatment with methotrexate in RA may not reflect real world practice: A systematic review and assessment of pragmaticism. , 2019 .

[2]  G. Guyatt,et al.  Development of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Summary of Findings (SoF) Table for Network Meta-analysis. , 2019, Journal of clinical epidemiology.

[3]  J. Pope,et al.  Randomized Trials, Meta-Analyses, and Systematic Reviews: Using Examples from Rheumatology. , 2018, Rheumatic diseases clinics of North America.

[4]  Elie A Akl,et al.  SERIES: LIVING SYSTEMATIC REVIEWS Living systematic review: 1. Introduction d the why, what, when, and how , 2022 .

[5]  Neil R. Smalheiser,et al.  Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowdsourcing approach , 2017, J. Am. Medical Informatics Assoc..

[6]  C. Bombardier,et al.  Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. , 2016, The Cochrane database of systematic reviews.

[7]  C. Bombardier,et al.  Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis , 2016, British Medical Journal.

[8]  Charles King,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[9]  Nicky J Welton,et al.  Automated generation of node‐splitting models for assessment of inconsistency in network meta‐analysis , 2015, Research synthesis methods.

[10]  Rebecca M. Turner,et al.  Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data , 2015, Journal of clinical epidemiology.

[11]  Mohammad Hassan Murad,et al.  A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis , 2014, BMJ : British Medical Journal.

[12]  T. Vos,et al.  The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study , 2014, Annals of the rheumatic diseases.

[13]  P. Tugwell,et al.  Updated Method Guidelines for Cochrane Musculoskeletal Group Systematic Reviews and Metaanalyses , 2014, The Journal of Rheumatology.

[14]  Yoshiya Tanaka,et al.  Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib , 2014, Expert opinion on pharmacotherapy.

[15]  D. M. van der Heijde,et al.  Proposal for a new nomenclature of disease-modifying antirheumatic drugs , 2013, Annals of the rheumatic diseases.

[16]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 2 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[17]  G. Firestein.  69 – Etiology and Pathogenesis of Rheumatoid Arthritis , 2013 .

[18]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[19]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[20]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[21]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[22]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[23]  G. A. Bennett,et al.  1958 revision of diagnostic criteria for rheumatoid arthritis. , 1958, Arthritis and rheumatism.

[24]  P. V. van Riel,et al.  DAS remission cut points. , 2006, Clinical and experimental rheumatology.

[25]  T. Pincus,et al.  Development of a multi-dimensional health assessment questionnaire (MDHAQ) for the infrastructure of standard clinical care. , 2005, Clinical and experimental rheumatology.

[26]  P. Ory,et al.  Interpreting radiographic data in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[27]  T. Lumley.  Network meta‐analysis for indirect treatment comparisons , 2002, Statistics in medicine.

[28]  Andrew Gelman,et al.  General methods for monitoring convergence of iterative simulations , 1998 .

[29]  Douglas G Altman,et al.  The relation between treatment benefit and underlying risk in meta-analysis , 1996, BMJ.

[30]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[31]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[32]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .

[33]  M. V. van Leeuwen,et al.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. , 1992, Annals of the rheumatic diseases.

[34]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[35]  J. Fries,et al.  The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. , 1982, The Journal of rheumatology.